|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects显示文摘 | Alejandro Forner María E. Reig Carlos Rodriguez de Lope Jordi Bruix | 2010 | Semin Liver Dis2010，，01： | 5 |
| 2 | Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design显示文摘 | Maria Reig Jordi Rimola Ferran Torres Anna Darnell Carlos Rodriguez‐Lope Alejandro Forner Neus LLarch José Ríos Carmen Ayuso Jordi Bruix | 2013 | Hepatology2013，，6： | 2 |
| 3 | Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction显示文摘In vivo genome editing represents a powerful strategy for both understanding basic biology and treating inherited diseases.However,it remains a challenge to develop universal and efficient in vivo genome-editing tools for tissues that comprise diverse cell types in either a dividing or non-dividing state.Here,we describe a versatile in vivo gene knock-in methodology that enables the targeting of a broad range of mutations and cell types through the insertion of a minigene at an intron of the target gene locus using an intracellularly linearized single homology arm donor.As a proof-of-concept,we focused on a mouse model of prematureaging caused by a dominant point mutation,which is difficult to repair using existing in vivo genome-editing tools.Systemic treatment using our new method ameliorated aging-associated phenotypes and extended animal lifespan,thus highlighting the potential of this methodology for a broad range of in vivo genome-editing applications. | Keiichiro Suzuki Mako Yamamoto Reyna Hernandez-Benitez Zhe Li Christopher Wei Rupa Devi Soligalla Emi Aizawa Fumiyuki Hatanaka Masakazu Kurita Pradeep Reddy Alejandro Ocampo Tomoaki Hishida Masahiro Sakurai Amy NNemeth Estrella Nunez Delicado Josep MCampistol Pierre Magistretti Pedro Guillen Concepcion Rodriguez Esteban Jianhui Gong Yilin Yuan Ying Gu Guang-Hui Liu Carlos Lopez-Otin Jun Wu Kun Zhang Juan Carlos Izpisua Belmonte | 2019 | Cell Research2019，29，10： | 2 |
| 4 | Management of HCC显示文摘 | Carlos Rodriguez de Lope Silvia Tremosini Alejandro Forner Maria Reig | 2012 | Journal of Hepatology2012，，： | 1 |
| 5 | Hilbert transform analysis of a time series of speckle interferograms with a temporal carrier显示文摘 | Fernando A Marengo Rodriguez Alejandro Federico Guillermo H Kaufmann | 2008 | Applied Optics2008，47，9： | 1 |
| 6 | A randomized trial of dental brushing for preventing ventilator-associated pneumonia显示文摘 | Angel Pobo Thiago Lisboa Alejandro Rodriguez | | 0，，02： | 1 |
| 7 | Mutual synchronization of robots via estimated state feed- back:a cooperative approaeh显示文摘 | Alejandro Rodriguez - Angeles Nijmeiier Henk | 2004 | IEEE Transactions on Control Systems Technology2004，，： | 1 |
| 8 | Improvement of TCF bleaching of olive tree pruning residue pulp by addition of a laccase AND/ OR xylanase pre-treatment 显示文摘 | Raquel Martin-Sampedro Alejandro Rodriguez et al | 2012 | BioResources2012，7，2： | 1 |
| 9 | Use of rheologieal compatibility criteria to study SBS modified asphalts 显示文摘 | Yvonne Becker M Alejandro J Muller Yajaira Rodriguez | 2003 | J Appl Polym Sci2003，90，： | 1 |
| 10 | The Most-Favored Na tion Clause in International Investment Agreements:A Tool for Treaty Shopping显示文摘 | Rodriguez Alejandro Faya | 2008 | Journal of International Arbitration2008，25，1： | 1 |
| 11 | Cerebral Oxygen Desaturation Predicts Cognitive Decline and Longer Hospital Stay After Cardiac Surgery显示文摘 | James P. Slater Theresa Guarino Jessica Stack Kateki Vinod Rami T. Bustami John M. Brown Alejandro L. Rodriguez Christopher J. Magovern Thomas Zaubler Kenneth Freundlich Grant V.S. Parr | 2009 | The Annals of Thoracic Surgery2009，，1： | 1 |
| 12 | Oral care practices in intensive care units: a?survey of 59 European ICUs显示文摘 | Jordi Rello Despoina Koulenti Stijn Blot Rafael Sierra Emili Diaz Jan J. Waele Antonio Macor Kemal Agbaht Alejandro Rodriguez | 2007 | Intensive Care Medicine2007，，6： | 1 |
| 13 | First-line cisplatin,docetaxel,and cetuximab for patients with recurrent or metastatic head and neck cancer:A multicenter cohort study显示文摘BACKGROUND The targeted therapy cetuximab[directed at the epidermal growth factor receptor(EGFR)]in combination with 5-fluorouracil and platinum-based chemotherapy(the EXTREME regimen)has shown substantial efficacy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck(R/M SCCHN).Thus,this scheme has been established as the preferred first-line option for these patients.However,more recently,a new strategy combining platinum,taxanes,and cetuximab(the TPEx regimen)has demonstrated similar efficacy with a more favorable toxicity profile in clinical trials.AIM To evaluate the safety and efficacy of the TPEx scheme as first-line therapy in advanced SCCHN in a multicenter cohort study.METHODS This retrospective multicenter cohort study included patients with histologically confirmed recurrent or metastatic SCCHN treated with first-line TPEx at five medical centers in Argentina between January 1,2017 and April 31,2020.Chemotherapy consisted of four cycles of docetaxel,cisplatin,and cetuximab followed by cetuximab maintenance therapy.Clinical outcomes and toxicity profiles were collected from medical charts.Treatment response was assessed by the investigator in accordance with Response Evaluation Criteria in Solid Tumors(version 1.1).Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events(version 4.0).RESULTS Twenty-four patients were included.The median age at diagnosis was 58 years(range:36-77 years).The majority of patients(83.3%)received at least four chemotherapy cycles in the initial phase.In the included group,the overall response rate was 62.5%,and 3 patients achieved a complete response(12.5%).The median time to response was 2.4 mo[95% confidence interval(CI):1.3-3.5].With a median follow-up of 12.7 mo(95%CI:8.8-16.6),the median progression-free survival(PFS)was 6.9 mo(95%CI:6.5-7.3),and the overall survival rate at 12 mo was 82.4%.Patients with documented tumor response showed a better PFS than those with disease stabilization or progression[8.5 mo(95%CI:5.5-11.5)and 4.5 mo(95%CI:2.5-6.6),respectively;P=0.042].Regarding the safety analysis,two-thirds of patients reported at least one treatment-related adverse event,and 25% presented grade 3 toxicities.Of note,no patient experienced grade 4 adverse events.CONCLUSION TPEx was an adequately tolerated regimen in our population,with low incidence of grade 3-4 adverse events.The median PFS were consistent with those in recent reports of clinical trials evaluating this treatment combination.This regimen may be considered an attractive therapeutic strategy due to its simplified administration,decreased total number of chemotherapy cycles,and treatment tolerability. | Agustin Falco Mariano Leiva Albano Blanco Guido Cefarelli Andres Rodriguez Juan Melo Federico Cayol Manglio Miguel Rizzo Alejandro Sola Hernan Rodriguez Montani Matias Chacon Diego Enrico Federico Waisberg | 2022 | World Journal of Clinical Oncology2022，13，2： | 1 |
| 14 | HLA-DQ:Celiac disease vs inflammatory bowel disease显示文摘AIM To determine the genetic predisposition to celiacdisease(Ce D) in inflammatory bowel disease(IBD) patients by quantifying the frequency of Ce D-related human leucocyte antigen(HLA)(HLA-Ce D: HLA-DQ2 and-DQ8) in IBD patients globally, by type of IBD and gender, and by calculating the protective/risk contribution of these haplotypes in the development of the IBD disease.METHODS We conducted a prospective study with IBD patients from our Unit. Clinical information was gathered and blood was tested for HLA-CeD. The control group was made up of unrelated Valencian organ donors.RESULTS1034 subjects were analyzed: 457 IBD [207 ulcerative coliti(UC) and 250 Crohn's disease(CD)] patients and 577 healthy controls. 39% of the controls and 34% of the patients had HLA-Ce D(P = 0.0852). HLA-DQ2 was less frequent in UC patients(P = 0.0287), and HLA-DQ8 in CD(P = 0.0217). In women with UC, the frequency of DQ2.5 cis(DQB1*02:01-DQA1*05:01) was reduced ≥ 50% [P = 0.0344; preventive fraction(PF) = 13%]. PFs(7%-14%) were obtained with all HLACe D haplotypes. HLA DQB1*02:02-DQA1*02:01(HLADQ2.2) was more frequent in CD patients with respect to controls(P = 0.001) and UC patients(etiological fraction = 15%).CONCLUSION HLA-CeD is not more frequent in IBD patients, with an even lower frequency of HLA-DQ2 and-DQ8 in UC and CD respectively. HLA-DQ2.5 confers protection from the development of UC, especially in women, and HLADQ8 does so for the appearance of CD. HLA-DQ2.2 is present in 34% of the CD patients and may constitute a genetic risk factor for CD development. | Marta Maia Bosca-Watts Miguel Minguez Dolores Planelles Samuel Navarro Alejandro Rodriguez Jesus Santiago Joan Tosca Francisco Mora | 2018 | World Journal of Gastroenterology2018，24，1： | 1 |
| 15 | A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR ?/? mice upon lethal virus challenge显示文摘 | Hani Boshra Gema Lorenzo Fernando Rodriguez Alejandro Brun | 2011 | Vaccine2011，，27： | 1 |
| 16 | Immunomodulatory oligonucleotide IMT504:Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy显示文摘The immune responses of humans and animals to insults(i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged proinflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell(MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy. | Jorge Zorzopulos Steven M Opal Andrés Hernando-Insúa Juan M Rodriguez Fernanda Elías Juan Fló Ricardo A López Norma A Chasseing Victoria A Lux-Lantos Maria F Coronel Raul Franco Alejandro D Montaner David L Horn | 2017 | World Journal of Stem Cells2017，9，3： | 1 |
| 17 | Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects显示文摘 | Alejandro Forner María E. Reig Carlos Rodriguez de Lope Jordi Bruix | 2010 | Semin Liver Dis2010，，01： | 1 |
| 18 | Development of adaptive injection flow rate and pressure control algorithms for resin transfer molding 显示文摘 | Omar Restrepo Kuang-Ting Hsiao Alejandro Rodriguez b | 2007 | Composites: Part A(S1359-835X)2007，38，6： | 1 |
| 19 | Intensive care adult patients with severe respiratory failure caused by influenza A ( H1N1 ) in Spain显示文摘 | Jordi Rello Alejandro Rodriguez Pedro Ibanez | 2009 | Critical Care2009，13，5： | 1 |
| 20 | Time dependence of the aroma pattern emitted by an encapsulated essence studied by means of eleclronic noses and chemometric analysis 显示文摘 | Rodriguez S D Maria E M Alejandro C O | 2010 | Food Research International2010，43，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员